Literature DB >> 20602489

Partial hexasomy for the Prader-Willi-Angelman syndrome critical region due to a maternally inherited large supernumerary marker chromosome.

Nicole L Hoppman-Chaney1, D Brian Dawson, Lai Nguyen, Sunanda Sengupta, Kara Reynolds, Elizabeth McPherson, Gopalrao Velagaleti.   

Abstract

Extra copies of the Prader-Willi-Angelman syndrome critical region (PWASCR) have been shown to have detrimental phenotypic effects depending on the parent of origin. Hexasomy for the PWASCR is rare; only 6 cases have been described to date. We report on a 15-year-old girl referred for developmental delay and seizures with a mosaic tricentric small marker chromosome (SMC) 15 identified by routine G-banding chromosome studies. C-banding and FISH confirmed the presence of three chromosome 15 centromeres as well as four copies of the PWASCR on the SMC in approximately 60% of interphase cells. Microsatellite genotyping documented maternal inheritance of the SMC, and methylation-sensitive multiplex ligation-dependent PCR amplification (MS-MLPA) showed that the extra copies of the PWASCR contained on the marker chromosome bear a methylation pattern similar to a normal maternal chromosome, implying maternal inheritance. These findings are consistent with the patient's phenotype as paternal inheritance of such a marker chromosome is thought to be benign. However, this patient's phenotype is the mildest described to date and may be a result of mosaicism for the SMC.

Entities:  

Mesh:

Year:  2010        PMID: 20602489     DOI: 10.1002/ajmg.a.33483

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  1 in total

1.  Multiplex ligation dependent probe amplification (MLPA) for rapid distinction between unique sequence positive and negative marker chromosomes in prenatal diagnosis.

Authors:  Diane Van Opstal; Marjan Boter; Petra Noomen; Malgorzata Srebniak; Guus Hamers; Robert-Jan H Galjaard
Journal:  Mol Cytogenet       Date:  2011-01-14       Impact factor: 2.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.